Researchers found dapagliflozin reduced the risk of progressive kidney disease by half in FSGS patients over a 2.4-year period, with good tolerability and safety. The medication stabilizes renal function and improves clinical outcomes in patients with type 2 diabetes and concomitant kidney damage.
A study found that using ultrasound to monitor lung congestion in hemodialysis patients with high cardiovascular risk improved patient outcomes. The technique reduced episodes of decompensated heart failure and cardiovascular events by 37% and 63%, respectively.
Researchers have identified the alternative complement pathway as a key driver of IgA nephropathy, a chronic kidney disease. Iptacopan, an oral inhibitor of Factor B, has been shown to significantly reduce proteinuria and stabilize renal function in patients with IgAN, offering a new therapeutic approach.
Researchers found that antiphospholipid antibodies bind to a specific complex in the body, triggering an autoimmune response that can lead to severe inflammation and organ damage. The study suggests that immunomodulatory therapies used for autoimmune diseases like SLE may also be effective in treating COVID-19.
Researchers found COVID-19 causes a wide range of organs, including the kidneys, resulting in acute kidney injury (AKI) with significant mortality rates. Studies showed viruses were directly detected in kidneys of deceased patients, correlating with age and comorbidities.
Studies have shown that COVID-19-associated nephritis can predict disease severity and mortality, while early signs of kidney involvement are associated with worse outcomes. Chronic kidney disease is a risk for some patients, particularly those who experience acute kidney injury (AKI), which may not recover fully.
The ACCOLADE study found that avacopan slowed C3 glomerulopathy progression by 20.6% in the placebo group but improved by 0.2% in the avacopan group, with patients with low eGFR benefiting from therapy. Avacopan also reduced proteinuria and increased eGFR in both groups.
Climate change is linked to environmental factors causing 24% of global deaths, including chronic kidney disease and acute kidney injury. The healthcare sector contributes to climate crisis, producing 4.4% of the global carbon footprint. Nephrologists play a crucial role in addressing climate change.
SGLT2 inhibitors like gliflozins reduce the risk of progressing to end-stage kidney disease in both diabetic and non-diabetic patients. The kidneys produce less erythropoietin as a result, which reduces anemia, resulting in reduced renal endpoint, cardiovascular events, and mortality
The 58th ERA-EDTA Congress features presentations on groundbreaking studies for C3 glomerulopathy, primary IGA nephropathy, focal segmental glomerosclerosis, and end-stage kidney disease. Expert insights into treatment strategies will be shared during the virtual press conference.
The N-PATH project will train 40 young European nephrologists from 6 countries through a two-year educational path with hands-on training and online lessons. The course is funded by the European Commission and will provide innovative advanced training in interventional nephrology.
ERA-EDTA has launched a series of e-seminars to apply recent trial findings to patient care. The e-seminars focus on topics like SGLT2 inhibitors and COVID-19, aiming to provide nephrology experts with insights into the benefits and risks of new treatments.
Two randomized controlled studies demonstrate that SGLT2 inhibitors can slow CKD progression across all patient groups, not just those with diabetes. The DAPA-CKD trial found a significant reduction in kidney function decline and end-stage disease with dapagliflozin treatment.
Cystatin C provides a more accurate estimate of kidney function than traditional methods, reducing errors in diagnosis and treatment planning. The new cystatin-based eGFR estimation method has the potential to improve patient outcomes for those with cardiovascular disease.
A study analyzed 363 young dialysis patients and identified key risk factors for 5-year mortality, including low albumin and elevated lactate dehydrogenase. Multimodal intervention strategies are crucial to reduce mortality risk among pediatric and adolescent dialysis patients.
Characterized by predominant tubulo-interstitial injury, the study highlights the importance of follow-up nephrological care to prevent long-term complications
A study found that SARS-CoV-2 infection led to renal Fanconi syndrome in 75% of hospitalized COVID-19 patients, characterized by proteinuria, phosphate loss, and increased uric acid excretion. The condition often preceded severe acute kidney injury, and intensive care patients were more frequently affected.
A recent study found that SARS-CoV-2 can induce kidney injury in patients, particularly those with high blood pressure and APOL1 gene variants. The virus triggers an inflammatory reaction, leading to collapsing glomerulopathy and tubular damage, even in the absence of direct viral infection.
The ADVOCATE study demonstrates avacopan's effectiveness in reducing corticoid use and achieving sustained remission in patients with AAV, particularly those with renal involvement. The treatment also showed improved outcomes with lower infection rates compared to standard immunosuppressive therapy.
A randomized trial found that rituximab reduces the risk of relapse by 64% compared to azathioprine, with fewer severe adverse events. The study suggests that rituximab may be a superior treatment option for patients with ANCA-associated vasculitis, particularly those with history of relapses.
The BLISS-LN study showed that belimumab added to standard therapy resulted in a significantly better primary renal response at 2 years, with 43% showing improvement versus 32% on placebo. Additionally, patients treated with belimumab had a 50% lower risk of experiencing renal events associated with poor prognosis.
A Phase 3 study found lumasiran to be effective in reducing 24hr urinary oxalate excretion by 65.4% and normalizing oxalate levels in patients with PH1. The treatment also showed an encouraging safety profile, with mild injection-site reactions being the most common adverse event.
Researchers analyzed EMPA-REG OUTCOME trial data to investigate impact of initial 'eGFR dip' on kidney outcomes. Diuretic use and higher KDIGO risk category were predictive factors for 'eGFR dip', but no significant impact on risk reduction
A recent analysis found that kidney transplant patients are at a higher risk of death from COVID-19, with advanced age being the most significant factor. The study, conducted on ERACODA database, showed that 21% of kidney transplant recipients died within 28 days, compared to 25% of dialysis patients.
A recent study found that COVID-19 patients with kidney disease have a poor prognosis and increased risk of in-hospital death. The study also showed that the kidneys are a target organ for the virus, with viral load detected in renal tubules and glomerular cells.
A study of COVID-19 cases among dialysis patients in Spain found a significantly higher rate of infection and mortality compared to the general population. The mortality rate among these patients was found to be influenced by factors such as age, lymphopenia, and elevated LDH levels.
A new study published in NDT found that elderly patients (older than 75 years) who received kidney transplants from similarly aged donors remained dialysis-free for the rest of their lives. The study's results suggest that transplantation is beneficial for this age group, with excellent graft survival rates.
A high-protein diet may boost chronic kidney disease and increase the risk of de novo kidney diseases, says a new study. Experts warn that patients with diabetes or obesity who follow a high-protein diet may be at risk of severe kidney damage.
A multicenter trial found that linagliptin reduced albuminuria but had no significant effect on eGFR or cardiovascular risk in patients with diabetes. The study also suggested that stratifying patients with nephrotic-range proteinuria could lead to better outcomes.
The VITALE study found that high-dose vitamin D supplementation significantly reduces fracture risk in kidney transplant recipients, with a lower incidence of fractures in the high-dose group compared to the low-dose group. The treatment was well-tolerated with no increased risks of adverse effects.
The Nephrology and Public Policy Committee (NPPC) has outlined a research plan to stimulate collaboration and grant applications in Europe. The plan focuses on addressing the global spread of kidney diseases, improving diagnostic tests, and enhancing patient care.
A study of 496,989 US patients found that those employed 6 months prior to dialysis initiation had lower mortality rates and higher transplant rates compared to unemployed individuals. The study highlights the importance of employment in improving quality of life and health outcomes for haemodialysis patients.
A new biomarker, urinary DKK3, has been identified as a predictor of acute kidney injury (AKI) in patients undergoing cardiac surgery. High preoperative levels of DKK3 are associated with lower kidney function and increased risk of AKI.
The UBI trial found that sodium bicarbonate treatment delayed progression of chronic kidney disease, reducing the risk of death by 57% and hospitalizations. The study also showed a significant delay in creatinine doubling time, translating to a relative risk reduction of 64%.
Chronic kidney disease (CKD) is associated with increased cardiovascular risk due to high LDL-C levels. PCSK9 inhibitors like evolocumab and alirocumab have shown promise in reducing cardiovascular events, but more research is needed to prove their efficacy and safety in CKD patients.
A new approach is needed for clinical trials in dialysis patients to address high morbidity and mortality. Innovative RCT designs, such as pragmatic clinical trials and adaptive platform designs, can improve the success of testing interventions in ESRD.
Researchers identified several potential therapeutic targets for Alport syndrome, including bardoxolone and anti-miRNA21. The disease is characterized by progressive kidney damage and proteinuria, and current treatments are primarily aimed at slowing disease progression rather than halting it.
A new SGLT2 inhibitor medication has been shown to significantly slow the progression of chronic kidney disease (CKD) in patients with diabetes. The CREDENCE trial demonstrated a 34% reduction in the risk of end-stage kidney disease, as well as improved cardiovascular outcomes.
Kidney transplant patients face a higher risk of cardiovascular complications and mortality due to existing damage and immunosuppressive drug side effects. The current post-transplantation care is fragmented, leading to undertreatment of modifiable cardiovascular risk factors.
A recent study found that kidney disease can trigger cognitive impairment even in its early stages, affecting approximately one in two patients. The cognitive decline is not age-related and worsens with declining kidney function.
A new analysis shows that men are affected by kidney failure much more often than women, with a 2.7 times higher incidence in older patients. Lifestyle changes, such as reducing blood pressure through exercise and losing weight, may help prevent kidney function decline.
A multinational collaboration study on familial primary distal renal tubular acidosis found that patients with adequate treatment had better growth and kidney function compared to those with inadequate treatment. The study, which included data from 340 patients across 29 countries, also highlighted the importance of controlling acid-ba...
A streamlined process for low-risk kidney transplant candidates has been developed to maximize the chance of pre-emptive transplantation. Younger patients with few comorbidities and not on dialysis for over five years can expect a significantly longer life expectancy after transplantation.
A study reveals that nephrologists treat the most complex patients, with kidney disease patients having the highest number of comorbidities and medication needs. The findings highlight the need for better financial funding and awareness for kidney diseases in European healthcare systems.